Relationship between non-invasively detected liver fibrosis and in-hospital outcomes in patients with acute coronary syndrome undergoing PCI

[1]  C. Gaudio,et al.  D-dimer for risk stratification and antithrombotic treatment management in acute coronary syndrome patients: a systematic review and metanalysis , 2021, Thrombosis Journal.

[2]  C. Gaudio,et al.  Low serum albumin levels and in-hospital outcomes in patients with ST segment elevation myocardial infarction. , 2021, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[3]  S. Iurciuc,et al.  Non-Alcoholic Fatty Liver Disease and Cardiovascular Comorbidities: Pathophysiological Links, Diagnosis, and Therapeutic Management , 2021, Diagnostics.

[4]  D. Dumitrascu,et al.  Acute Coronary Syndromes and Nonalcoholic Fatty Liver Disease: “Un Affaire de Coeur” , 2020, Canadian journal of gastroenterology & hepatology.

[5]  Deepak L. Bhatt,et al.  2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. , 2020, European heart journal.

[6]  E. Mikhaylov,et al.  The prognostic role of high-sensitivity C-reactive protein in patients with acute myocardial infarction , 2020, Journal of geriatric cardiology : JGC.

[7]  G. Hu,et al.  Association between liver fibrosis scores and the risk of mortality among patients with coronary artery disease. , 2020, Atherosclerosis.

[8]  Y. Turan.  The Nonalcoholic Fatty Liver Disease Fibrosis Score Is Related to Epicardial Fat Thickness and Complexity of Coronary Artery Disease , 2020, Angiology.

[9]  G. Carpino,et al.  Increased Liver Localization of Lipopolysaccharides in Human and Experimental NAFLD , 2019, Hepatology.

[10]  J. Koskinas,et al.  Liver fibrosis staging with combination of APRI and FIB-4 scoring systems in chronic hepatitis C as an alternative to transient elastography , 2019, Annals of gastroenterology.

[11]  Jin Mo Yang,et al.  Noninvasive Serum Fibrosis Markers are Associated with Coronary Artery Calcification in Patients with Nonalcoholic Fatty Liver Disease , 2019, Gut and liver.

[12]  M. Friedrich-Rust,et al.  Use of Antiplatelet Agents Is Inversely Associated With Liver Fibrosis in Patients With Cardiovascular Disease , 2018, Hepatology communications.

[13]  A. Farcomeni,et al.  Incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonist oral anticoagulants. , 2018, International journal of cardiology.

[14]  Sai Zhang,et al.  Predictive value of neutrophil to lymphocyte ratio in patients with acute ST segment elevation myocardial infarction after percutaneous coronary intervention: a meta-analysis , 2018, BMC Cardiovascular Disorders.

[15]  L. Räber,et al.  Prognosis of cardiovascular and non-cardiovascular multimorbidity after acute coronary syndrome , 2018, PloS one.

[16]  F. Violi,et al.  Localization of lipopolysaccharide from Escherichia Coli into human atherosclerotic plaque , 2018, Scientific Reports.

[17]  Marco Valgimigli,et al.  2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). , 2018, European heart journal.

[18]  F. Violi,et al.  Gut‐Derived Serum Lipopolysaccharide is Associated With Enhanced Risk of Major Adverse Cardiovascular Events in Atrial Fibrillation: Effect of Adherence to Mediterranean Diet , 2017, Journal of the American Heart Association.

[19]  F. Violi,et al.  Lipopolysaccharide as trigger of platelet aggregation via eicosanoid over-production , 2017, Thrombosis and Haemostasis.

[20]  M. Rayner,et al.  Cardiovascular disease in Europe: epidemiological update 2016. , 2016, European heart journal.

[21]  D. Adams,et al.  Platelets: No longer bystanders in liver disease , 2016, Hepatology.

[22]  Andrew E Moran,et al.  Global and Regional Patterns in Cardiovascular Mortality From 1990 to 2013 , 2015, Circulation.

[23]  V. Fuster,et al.  Utilization of and Adherence to Guideline-Recommended Lipid-Lowering Therapy After Acute Coronary Syndrome: Opportunities for Improvement. , 2015, Journal of the American College of Cardiology.

[24]  T. Jernberg,et al.  Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. , 2015, European heart journal.

[25]  N. Brunetti,et al.  Endothelial Dysfunction Correlates with Liver Fibrosis in Chronic HCV Infection , 2015, Gastroenterology research and practice.

[26]  G. Sesti,et al.  Association between Noninvasive Fibrosis Markers and Cardio-Vascular Organ Damage among Adults with Hepatic Steatosis , 2014, PloS one.

[27]  R. Abbate,et al.  Nonalcoholic fatty liver in nondiabetic patients with acute coronary syndromes , 2013, European journal of clinical investigation.

[28]  J. Alpert,et al.  How to use high-sensitivity cardiac troponins in acute cardiac care. , 2013, European heart journal.

[29]  K. Cusi,et al.  The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association , 2012, The American Journal of Gastroenterology.

[30]  Jeroen J. Bax,et al.  ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation , 2012 .

[31]  A. Burt,et al.  Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease , 2022 .

[32]  A. Sanyal,et al.  Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[33]  Yun Zhang,et al.  Atherosclerotic plaque disruption induced by stress and lipopolysaccharide in apolipoprotein E knockout mice. , 2009, American journal of physiology. Heart and circulatory physiology.

[34]  H. Kirikoshi,et al.  Effectiveness of antiplatelet drugs against experimental non-alcoholic fatty liver disease , 2008, Gut.